Phase 2Not yet recruiting
Low-Dose Naltrexone For ME/CFS: Dose-Finding
Low-dose Naltrexone (LDN) for the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Dose-Finding
- Sponsor
- University of Alabama at Birmingham (Academic or other)
- Enrollment
- 75 planned
- Conditions
- Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
- Interventions
- Low-Dose Naltrexone, 1.5mg; Low-Dose Naltrexone, 3.0mg; Low-Dose Naltrexone, 4.5mg; Low-Dose Naltrexone, 6.0mg
- Ages
- adults, older adults
- Registry
- NCT07285473
Full record on ClinicalTrials.gov
From the registry
This exploratory clinical trial tests low-dose naltrexone (LDN) for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). A remote trial approach is used, with eligibility open to the state of Alabama.
Primary outcomes
- PROMIS Fatigue Short Form 7a
History
Primary completion expected
Started
Last registry update
Registered